10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System lessened its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 5.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 129,112 shares of the company’s stock after selling 7,008 shares during the quarter. California Public Employees Retirement System’s holdings in 10x Genomics were worth $7,225,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in TXG. Powell Investment Advisors LLC acquired a new stake in shares of 10x Genomics during the fourth quarter valued at about $200,000. AIA Group Ltd lifted its stake in 10x Genomics by 0.9% during the fourth quarter. AIA Group Ltd now owns 41,369 shares of the company’s stock worth $2,315,000 after purchasing an additional 365 shares in the last quarter. SVB Wealth LLC boosted its position in shares of 10x Genomics by 92.1% during the fourth quarter. SVB Wealth LLC now owns 1,446,552 shares of the company’s stock worth $80,949,000 after buying an additional 693,422 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of 10x Genomics by 32.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock valued at $127,786,000 after buying an additional 565,059 shares in the last quarter. Finally, Lecap Asset Management Ltd. purchased a new stake in shares of 10x Genomics in the 4th quarter valued at $643,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other 10x Genomics news, CEO Serge Saxonov sold 4,660 shares of 10x Genomics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $44.00, for a total transaction of $205,040.00. Following the transaction, the chief executive officer now owns 842,900 shares of the company’s stock, valued at $37,087,600. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Justin J. Mcanear sold 1,865 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $86,424.10. Following the transaction, the chief financial officer now owns 95,240 shares of the company’s stock, valued at $4,413,421.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Serge Saxonov sold 4,660 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the transaction, the chief executive officer now owns 842,900 shares in the company, valued at approximately $37,087,600. The disclosure for this sale can be found here. In the last three months, insiders sold 12,959 shares of company stock valued at $592,806. Insiders own 10.65% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. TD Cowen lowered shares of 10x Genomics from a “buy” rating to a “hold” rating and cut their price target for the stock from $57.00 to $32.00 in a research note on Wednesday. The Goldman Sachs Group reduced their target price on shares of 10x Genomics from $30.00 to $26.00 and set a “sell” rating on the stock in a report on Wednesday. Deutsche Bank Aktiengesellschaft dropped their price target on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. UBS Group reduced their price objective on 10x Genomics from $52.00 to $30.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Barclays cut their price target on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $48.50.

10x Genomics Stock Up 4.5 %

Shares of TXG opened at $27.48 on Friday. 10x Genomics, Inc. has a 52-week low of $24.60 and a 52-week high of $63.57. The stock has a 50 day moving average price of $36.16 and a 200 day moving average price of $42.18. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -12.24 and a beta of 1.94.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The firm had revenue of $141.01 million for the quarter, compared to the consensus estimate of $142.24 million. During the same period last year, the firm posted ($0.44) EPS. The company’s revenue was up 5.0% on a year-over-year basis. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.47 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.